SEARCH

Current Edition

drugmakers

FDA, as expected, rejects Lilly and Innovent immunotherapy in signal to drugmakers

Dive Brief: The Food and Drug Administration has rejected an experimental cancer immunotherapy Eli Lilly and partner Innovent Biologics have been developing for a common …

Continue Reading →
drugmakers

J&J to explore RNA reprogramming with Remix research deal

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest …

Continue Reading →
bottomed out

After years of decline, drugmakers’ price hikes may have bottomed out

Double-digit list price increases for branded medicines in the middle of the last decade put drugmakers in political crosshairs. Under criticism and pressure, those boosts …

Continue Reading →
cancer immunotherapy

Latest Roche results show promise for new type of cancer immunotherapy

Though drugmakers have spent considerable resources trying to expand the reach of immunotherapy through new drug combinations, success has been hard to find. Multiple high-profile …

Continue Reading →
Biotech

Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

Lengo’s drug targets a mutation in the gene that drives production of a protein called EGFR, which, in turn, can help spur tumor growth. The …

Continue Reading →
coronavirus

Vaccine makers move quickly to confront omicron threat

Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant. Facing a coronavirus variant that experts …

Continue Reading →
Atea

Atea, Roche change plans for oral COVID-19 drug after trial setback

Atea’s fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. …

Continue Reading →
drugmakers

Sanofi claims positive early data for mRNA COVID shot, but pivots to flu instead

When drugmakers geared up to respond to the pandemic, Sanofi and GSK, as two of the largest vaccine makers, were expected to make a major …

Continue Reading →
Bristol Myers Squibb

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. …

Continue Reading →
Acadia Pharmaceuticals

FDA rejects a biotech’s kidney drug, but some analysts still see a ‘sliver of hope’

The FDA’s decision wasn’t surprising to analysts, as “deficiencies” in an approval application have become somewhat of a prelude to rejection. This year alone saw …

Continue Reading →
drugmakers

Pfizer’s fast progress shines spotlight on an emerging vaccine race

Drugmakers have laboured for decades to successfully develop a vaccine to protect infants and older people against infections of a common pathogen called respiratory syncytial …

Continue Reading →